“Ovarian cancer represents one of the leading cause of cancer-relateddeaths for women and is the most common gynecologic malignancy.In spite of relative low morbidity, ovarian cancer has a highfatality ratio, with overall 5-year survival of less than 30%.At present, there are inadequate treatment options for the managementof advanced ovarian cancer, and therefore development of novelapproaches for treatment of this disease are needed.
Cannabinoids,the active components of Cannabis sativa linnaeous and their derivatives have received considerable attention in recent yearsdue to their diverse pharmacological activities such as cell growth inhibition and tumor regression. To date, two differentcannabinoid receptors have been characterized and cloned frommammalian tissues: the “central” CB1 receptor and the “peripheral”CB2 receptor…
These results support a new therapeutic approach for the treatmentof ovarian cancer. It is also conceivable that with available cannabinoids as lead compounds, non-habit forming agents that have higher biological effects could be developed.”
http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/1084
http://cancerres.aacrjournals.org/content/66/8_Supplement/1084.1